NEW YORK (GenomeWeb News) – Strategic Diagnostics said today that it has signed an agreement to supply reagents to “a large manufacturer of in vitro diagnostics.”
 
The term of the agreement is five years, and the company said that it expects initial revenues of around $1 million per year, which are anticipated to “more than double” over the term of the agreement.
 
Strategic Diagnostics said it will begin shipping the reagents to the undisclosed client in the fourth quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.